01602nam a2200349Ia 4500001001200000003000600012005001700018007001400035008004100049020001500090020001800105040006300123074001900186088009000205086002300295099002300318110012000341245024500461260011400706300004500820336002600865337002700891338003100918500003500949504004100984500002601025500002501051533009501076650003201171650003001203999001901233ocm52452348OCoLC20180312141842.0he bmb024bbca030618s2003    dcua    bb   f000 0 eng d  a0160697115  a9780160697111  aFPSbengcFPSdOCLCQdFCMBLdOCLCQdOCLCOdOCLCQdGPOdMvI  a1019-B-01 (MF)  aSerial no. 107-143 (United States. Congress. House. Committee on Energy and Commerce)0 aY 4.C 73/8:107-143  aY 4.C 73/8:107-1431 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Oversight and Investigations.10aIssues relating to the safety of Accutane :bhearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, December 11, 2002.  aWashington :bU.S. G.P.O. :bFor sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],c2003.  aiii, 739 pages :billustrations ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  aShipping list no.:2003-0253-M.  aIncludes bibliographical references.  a"Serial no. 107-143."  aCRDP Program record.  aMicrofiche.bWashington :cSupt. of Docs., U.S. G.P.O.,d2003.e10 microfiches : negative. 0aIsotretinoinxSide effects. 0aIsotretinoinxToxicology.  c269573d269573